KLRS
Q3 2026 EPS Estimate
$-0.50
Aug 12, 2026 · Reports before open

Analyst Sentiment

Wall St. Consensus
Buy
1 analyst·Low coverage
75
Score
1 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$14.00
+215.3%
Consensus
$17.00
+282.9%
Bull
$23.00
+418.0%
12-Month Target Range1 analyst
$14.00$17.00$23.00
Current $4.44Consensus
Current Price
$4.44
Upside to Consensus
$12.56

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev
EPS
FY2029
Rev
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$10M$4M$11M
Low$10M$4M$11M
High$10M$4M$11M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-29M$-24M$-39M$-39M$-40M
Low$-34M$-27M$-58M$-39M$-40M
High$-25M$-22M$-20M$-39M$-40M
EPS Avg$-2.03$-1.63$-2.28$-2.56$-2.61
Low$-2.22$-1.79$-3.83$-2.56$-2.61
High$-1.64$-1.41$-1.32$-2.56$-2.61
Analysts (Rev / EPS) / 65 / 7 / 65 / 43 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-12M$-13M$-14M$-10M$-11M$-12M
Low$-14M$-13M$-14M$-10M$-11M$-12M
High$-9M$-13M$-14M$-10M$-11M$-12M
EPS Avg$-0.52$-0.55$-0.57$-0.44$-0.46$-0.51
Low$-0.59$-0.55$-0.57$-0.44$-0.46$-0.51
High$-0.40$-0.55$-0.57$-0.44$-0.46$-0.51
Analysts (Rev / EPS) / 7 / 3 / 3 / 2 / 2 / 2

Earnings Surprises

Recent Analyst Actions

May 14, 2026Wedbush
Kalaris Therapeutics initiated with an Outperform at Wedbush
Target:$17.00
+252.0%from $4.83
Apr 16, 2026Morgan Stanley
Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
Target:$14.00
+138.5%from $5.87
Mar 9, 2026Raymond James
Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS)
Target:$23.00
+141.9%from $9.51
Dec 23, 2025Chardan Capital
Kalaris Therapeutics initiated with a Buy at Chardan
Target:$19.00
+88.9%from $10.06
Jul 23, 2025Piper Sandler
Kalaris Therapeutics assumed with a Neutral at Piper Sandler
Target:$3.00
+16.7%from $2.57
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.